Hemophilias and von Willebrand’s Disease

1. THE 2-MINUTE PHYSIOLOGY (Rapid Pathophysiology)

Hemophilia A and B are X-linked recessive genetic disorders characterized by quantitative deficiencies of Factor VIII and Factor IX, respectively. Both are critical components of the intrinsic coagulation pathway. Their absence prevents the formation of the tenase complex, severely blunting the generation of thrombin. Without a robust thrombin burst, the conversion of fibrinogen to a stable fibrin cross-linked mesh fails, causing delayed, deep-tissue hemorrhage (e.g., hemarthroses, intramuscular hematomas).

von Willebrand Disease (vWD) is an autosomal dominant disorder of the von Willebrand Factor (vWF). vWF serves two critical roles: it mediates the initial adhesion of platelets to exposed subendothelial collagen (primary hemostasis), and it acts as a chaperone protein for Factor VIII, protecting it from rapid degradation. Deficiency leads to primarily mucocutaneous bleeding (epistaxis, menorrhagia) and, in severe variants, a secondary drop in Factor VIII.

The Inhibitor Threat: Up to 20% of hemophilia patients develop IgG alloantibody "inhibitors" against exogenous replacement factors. These antibodies neutralize standard factor infusions, creating an acquired, severe treatment-resistant state.

2. THE BEDSIDE ACTION PLAN (Rapid ER Management)

• The "Treat First, Test Later" Rule: In any hemophiliac with severe trauma, suspected intracranial hemorrhage (ICH), or airway compromise, administer factor replacement immediately before any imaging or invasive procedures.
• Hemophilia A/B Standard Resuscitation:
• Life-Threatening Bleeds (CNS, trauma, airway): Target 100% factor activity.
• Moderate Bleeds (hemarthrosis, severe epistaxis): Target 50% factor activity.
• The Inhibitor Protocol: For a bleeding patient with known high-titer inhibitors, standard factor replacement will fail. You must use bypassing agents to initiate clotting downstream:
• Administer Recombinant Factor VIIa (rFVIIa) at 90 mcg/kg IV.
• Alternatively, if the patient is not on emicizumab, administer Activated Prothrombin Complex Concentrate (aPCC/FEIBA) at 75 to 100 units/kg IV.
• von Willebrand Disease (Type 1): Administer Desmopressin (DDAVP) 0.3 mcg/kg IV/SC to trigger the release of stored vWF and Factor VIII from endothelial Weibel-Palade bodies. Severe vWD (Type 3) requires vWF-containing factor concentrates or cryoprecipitate.

3. THE DIAGNOSTIC GRID (Differential Diagnosis & Workup)

• Critical "Can't-Miss" Differential Diagnoses:
• Disseminated Intravascular Coagulation (DIC)
• Acquired Hemophilia (autoimmune inhibitor development in a previously healthy adult)
• Vitamin K deficiency / Warfarin toxicity
• Severe Liver Disease Coagulopathy
• Prioritized Diagnostic Workup:
• Coagulation Panel: Expect a normal PT and a prolonged aPTT in Hemophilia A/B and severe vWD.
• The Mixing Study: If the aPTT is prolonged, mix the patient's plasma 1:1 with normal plasma. If it corrects, the patient has a factor deficiency. If it fails to correct, the patient has a circulating inhibitor.
• Platelet Count: Strictly normal in both Hemophilia and vWD (vWD is a qualitative platelet dysfunction, not quantitative).
• Biomarker Assays: Factor VIII, Factor IX, and vWF antigen levels (often drawn in the ED but resulted later).

4. THE VISUAL BOARD (ECG / POCUS / Imaging)

• CT Head (Non-Contrast): The gold standard for any hemophiliac presenting with head trauma or altered mental status. You must look for subdural, epidural, or intraparenchymal bleeding. Do not delay factor infusion to obtain this scan.
• Point-of-Care Ultrasound (POCUS):
• Joints: Use a high-frequency linear probe to evaluate for hemarthrosis (most commonly the knee, elbow, or ankle). Look for an anechoic or complex echogenic fluid collection displacing the joint capsule.
• eFAST: Hemophiliacs are at high risk for spontaneous or traumatic solid organ rupture and retroperitoneal bleeding. Assess Morrison's pouch, the splenorenal recess, and the pelvis for free fluid.

5. THE SCORING MATRIX (Risk Stratification & Guidelines)

Emergency physicians must use strict, validated criteria to mandate empirical factor replacement. Absolute Indications for Factor Replacement in Hemophilia include:

• Any new or unusual headache, particularly following trauma, even if seemingly minor.
• Suspected bleeding into a joint or muscle.
• Any significant injury to the head, neck, mouth, or eyes.
• Severe pain or swelling at any location.
• All wounds requiring surgical closure (sutures, staples, adhesives).
• History of blunt trauma that might result in bleeding.
• Prior to any invasive ED procedure (e.g., lumbar puncture, central line, chest tube).
• Suspicion of uncontrolled GI or heavy menstrual bleeding leading to hypovolemia or anemia.

6. THE DANGER ZONE (Pitfalls & Critical Actions)

• Deadly Pitfall (Premature Closure): Dismissing a "minor" head bump in a hemophiliac. Even seemingly trivial head trauma requires empirical factor replacement to 100% activity and a CT scan.
• Deadly Pitfall (Inhibitors): Administering standard Factor VIII to a patient with a known history of IgG inhibitors. The factor will be immediately neutralized by the antibodies, leaving the patient unprotected.
• Critical Action: Recognizing that up to 20% of hemophilia patients have inhibitors, requiring immediate consultation with Hematology and the deployment of bypassing agents like Recombinant Factor VIIa (90 mcg/kg IV).

7. MCQ MASTERCLASS (Written Exam Tips)

• Buzzwords:
• "Hemarthrosis" or "deep muscle hematoma" = Hemophilia A or B.
• "Mucocutaneous bleeding," "epistaxis," or "menorrhagia" = von Willebrand Disease or platelet disorder.
• "Christmas Disease" = Hemophilia B (Factor IX).
• Distractor Trap: A question stem features a 60-year-old with spontaneous severe bruising and a prolonged aPTT. The mixing study fails to correct. The distractor option will be "Undiagnosed Hemophilia A." The correct answer is an "Acquired Factor VIII Inhibitor," because congenital hemophilia would successfully correct in a mixing study.
• Pharmacology Trap: Desmopressin (DDAVP) is offered as a treatment for Hemophilia B. This is incorrect. DDAVP only releases vWF and Factor VIII; it does nothing for a Factor IX deficiency.

8. THE BOARDROOM SCRIPT (OSCE & Oral Board Tips)

• The Triage & Action Phrase: "Given this patient's history of Hemophilia A and a minor head injury, I am highly concerned for life-threatening intracranial hemorrhage. I am immediately ordering empirical 100% Factor VIII replacement to be given as a rapid IV push right now, before we move to the CT scanner."
• Handling Complications: "The patient's family states he has a history of high-titer inhibitors. Standard factor replacement will be ineffective. I am altering my resuscitation to utilize a bypassing agent, specifically Recombinant Factor VIIa at 90 mcg/kg IV."
• The Joint Exam: "I will thoroughly examine the patient's joints, looking for warmth, swelling, and decreased range of motion indicating an acute hemarthrosis. I will splint the joint in a position of comfort and apply ice while the factor is infusing. I will not attempt diagnostic arthrocentesis, as it is contraindicated."